摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

1-[[4,5-双(4-甲氧基苯基)-2-噻唑]羰基]-4-甲基哌嗪盐酸盐

中文名称
1-[[4,5-双(4-甲氧基苯基)-2-噻唑]羰基]-4-甲基哌嗪盐酸盐
中文别名
——
英文名称
[4,5-bis(4-methoxyphenyl)-1,3-thiazol-2-yl]-(4-methylpiperazin-1-yl)methanone;hydron;chloride
英文别名
——
1-[[4,5-双(4-甲氧基苯基)-2-噻唑]羰基]-4-甲基哌嗪盐酸盐化学式
CAS
——
化学式
C23H26ClN3O3S
mdl
——
分子量
460.0
InChiKey
YWMAVHIKOAOSFM-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.3
  • 重原子数:
    31
  • 可旋转键数:
    5
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.3
  • 拓扑面积:
    83.1
  • 氢给体数:
    1
  • 氢受体数:
    6

文献信息

  • Thiazole compounds, processes for the preparation thereof, and pharmaceutical composition comprising the same
    申请人:FUJISAWA PHARMACEUTICAL CO., LTD.
    公开号:EP0377457A1
    公开(公告)日:1990-07-11
    The present invention relates to new thiazole compounds and pharmaceutically acceptable salts thereof which have pharmacological activities, processes for preparation thereof, a pharmaceutical composition comprising the same same and a use of the same.
    本发明涉及具有药理活性的新噻唑化合物及其药学上可接受的盐、其制备工艺、包含相同物质的药物组合物以及相同物质的用途。
  • USE OF COMPOUNDS FOR THE TREATMENT OF PAIN
    申请人:Akron Molecules AG
    公开号:EP2846788A1
    公开(公告)日:2015-03-18
  • NOVEL COMPOSITION FOR TREATING METABOLIC SYNDROME AND OTHER CONDITIONS
    申请人:Chen Chien-Hung
    公开号:US20120183600A1
    公开(公告)日:2012-07-19
    The invention relates to a composition that includes a first agent selected from the group consisting of an oxidative phosphorylation inhibitor, an ionophore, and an adenosine 5′-monophosphate-activated protein kinase (AMPK) activator; a second agent that possesses anti-inflammatory activity; and a third agent that possesses serotonin activity.
  • Methods for Reducing Recurrence of Tumors
    申请人:Beth Israel Deaconess Medical Center, Inc.
    公开号:US20190290614A1
    公开(公告)日:2019-09-26
    Methods of reducing the risk of cancer after surgery, e.g., of cancer recurrence, by administering COX-1 selective inhibitors prior to surgery or biopsy. Alternatively or in addition, other anti-platelet agents and/or TGF-β inhibition and/or IL-6 inhibition and/or inhibitors of the PD-1/PD-L1 axis, as well as combinations thereof.
  • US5217971A
    申请人:——
    公开号:US5217971A
    公开(公告)日:1993-06-08
查看更多